Riskpilot← Back to searchSign inGet full accessB/P-Pharma Aktiebolag
ABActiveOrg 5569349078Vårby Allé 18Retail sale of pharmaceutical products · NACE 4773Est. 20131-4 employees
Revenue 2025
SEK 16,3M
+10% vs 2024
EBITDA margin
2.4%
-55% vs 2024
Equity ratio
48.9%
Financial strength
Net profit 2025
SEK 294K
-46% vs 2024
| Revenue | SEK 16,3M | +10% |
| EBITDA | SEK 399K | -55% |
| Net profit | SEK 294K | -46% |
| Total assets | SEK 5,9M | -5% |
| Equity | SEK 2,9M | -7% |
| Employees | — | — |
Legal name
B/P-Pharma Aktiebolag
Org number
5569349078
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
19 juni 2013
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva handel med läkemedel dvs köpa och sälja receptbelagda, receptfria läkemedel, köpa och sälja hälsokostpreparat, egenvårdsartiklar och livsmedel.
Address
Vårby Allé 18
Phone
+4687491088
Email
info@varbygardapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 731 | 11 834 | 12 678 | 14 799 | 16 327 |
| Staff expenses | — | — | — | — | −2 487 |
| EBITDA | 178 | 325 | 538 | 896 | 399 |
| Depreciation & amort. | −16 | −8 | −206 | −222 | −237 |
| EBIT | 162 | 317 | 332 | 674 | 162 |
| Net financials | −1 | — | 1 | 4 | 1 |
| Profit before tax | 261 | 275 | 243 | 693 | 385 |
| Tax | −63 | −60 | −55 | −152 | −91 |
| Net profit | 198 | 215 | 188 | 541 | 294 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 762 | 4 695 | 5 129 | 6 187 | 5 852 |
| Equity | 2 122 | 2 336 | 2 524 | 3 065 | 2 859 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 1 634 | 1 309 | 1 466 | 1 998 | 2 092 |
| Total debt | 1 634 | 1 309 | 1 466 | 1 998 | 2 092 |
EBITDA margin
2.4%
This company
15.8%
Market median
-85% vs market
20212025
Equity ratio
48.9%
This company
38.2%
Market median
+28% vs market
20212025
Return on equity
10.3%
This company
18.4%
Market median
+44% vs market
20212025
Net profit margin
1.8%
This company
8.1%
Market median
-78% vs market
20212025
Asset turnover
2.79×
This company
1.12×
Market median
+149% vs market
20212025
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LG | Audit | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of B/P-Pharma Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gunnar Lundkvist | Audit | 0 companies |
| Behrouz Rezakhani | Board of Directors | 0 companies |
| Poopak Rahimi Rad | Deputy Board Member | 0 companies |
| Freidoun André Albertioni | Deputy Board Member | 0 companies |
| Resul Hamurcu | Board of Directors | 0 companies |